Navigation Links
Maxwell Biotech Venture Fund's Portfolio Company Hepatera LLC Announces Completion of Recruitment for Phase 2b Clinical Trials of Myrcludex B in Chronic Hepatitis Delta
Date:4/4/2017

MOSCOW, April 4, 2017 /PRNewswire/ --

Hepatera LLC and its development partner MYR GmbH today announced the completion of recruitment for MYR 202 and 203 clinical trials, a Phase 2b program investigating Myrcudex B in chronic hepatitis delta infection. 180 subjects have been enrolled in 20 centers in Russia and Germany.

Maxwell Biotech Venture Fund Logo
Maxwell Biotech Venture Fund Logo

     (Logo: http://photos.prnewswire.com/prnh/20140213/668442-b)

"We are pleased to participate in the MYR 202 trial and look forward to results of this world's largest study in this severe unmet medical need," said Heiner Wedemeyer, MD, Professor at Hannover Medical School and Chairman of MYR's Clinical Advisory Board.

"We are thankful for the enthusiastic collaboration of the participating centers, which has allowed us to meet the recruitment goals within the planed period," commented Dr. Dmitry Popov, Managing Partner of Maxwell Biotech Fund. "The interim results of MYR 202 will be available by the end of 2017."

About Myrcludex B 

Myrcludex B is a first-in-class entry inhibitor for treatment of chronic hepatitis B and D infections. The drug inhibits the recently identified HBV receptor on the hepatocyte surface and prevents the infection of the healthy cells and viral spreading within the liver.

About Hepatera 

The main activity of Hepatera Ltd. is the development of safe and effective drugs for the treatment of liver diseases for the Russian market. Myrcludex B is developed by the company in cooperation with the biotechnology company MYR, GmbH (Germany).

About MYR GmbH 

MYR GmbH is a clinical stage biotechnology company focused on drugs for treatment of chronic hepatitis B and D virus infections. The company was founded in 2010 and is based in Burgwedel, Germany. Myr GmbH is received investments from Maxwell Biotech Venture Fund and High-Tech Gründerfonds (HTGF).

About Maxwell Biotech Venture Fund 

Maxwell Biotech Venture Fund (MBVF) is the first Russian venture fund fully dedicated to investments in the life sciences sector. The Fund has been created with the participation of the Russian Venture Company (RVC). MBVF portfolio companies have nine innovative clinical stage drug candidates in development; four thereof are in Phase 2.


'/>"/>
SOURCE Maxwell Biotech Venture Fund
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Maxwell Biotech Venture Funds Portfolio Company Hepatera LLC Announces Start of Phase 2b Clinical Trial of Myrcludex B
2. Separation Systems for Commercial Biotechnology
3. Research Reports Coverage on Biotech Stocks -- Agenus, Intrexon, Progenics Pharma, and Concordia
4. Agricultural Biotechnology - Emerging Technologies & Global Markets - Driving Forces, Market Applications, Industry Structure & Competitive Dynamics - Research and Markets
5. Biotech Stocks on Investors Radar -- Portola Pharma, OvaScience, Ocera Therapeutics, and Ocular Therapeutix
6. On World Tuberculosis Day 2017, American/Russian biotech partnership announces positive trial results for a new treatment of TB
7. Biotech Stocks Under Scanner -- BioDelivery Sciences, Sage Therapeutics, Benitec Biopharma, and OncoGenex Pharma
8. Research Reports Initiation on Biotech Stocks -- Sangamo, Eyegate Pharma, Synthetic Biologics, and Regulus
9. Biotechs Focus on Improving Cancer Pain Management for Enhanced Patient Care
10. Three Day Biotechnology for the Non-Biotechnologist Course (London, United Kingdom - September 27-28-29, 2017) - Research and Markets
11. Festo Introduces at Interphex a New Family of Sanitary/Automated Ball, Angle Seat, and Pinch Valves for the Pharma and Biotech Industries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... ... Science Center’s FirstHand program has won a US2020 STEM Mentoring Award. Representatives of ... award for Excellence in Volunteer Experience from US2020. , US2020’s mission is to ...
(Date:10/10/2017)... ... 2017 , ... The Pittcon Program Committee is pleased to ... who have made outstanding contributions to analytical chemistry and applied spectroscopy. Each award ... conference and exposition for laboratory science, which will be held February 26-March 1, ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... 5, 2017, in the medical journal, Epilepsia, Brain Sentinel’s SPEAC® System which ... video EEG, in detecting generalized tonic-clonic seizures (GTCS) using surface electromyography (sEMG). ...
(Date:10/6/2017)... ... October 06, 2017 , ... On Tuesday, October 24th, ABC² ... the first-ever adaptive clinical trial for glioblastoma (GBM). The featured speaker will be ... and open to the public, but registration is required. , WHAT: ABC² ...
Breaking Biology Technology:
(Date:3/30/2017)... -- On April 6-7, 2017, Sequencing.com will host the world,s ... at Microsoft,s headquarters in Redmond, Washington ... health and wellness apps that provide a unique, personalized ... is the first hackathon for personal genomics and the ... the genomics, tech and health industries are sending teams ...
(Date:3/29/2017)... CHICAGO , March 29, 2017  higi, the ... ecosystem in North America , today ... Partners and the acquisition of EveryMove. The new investment ... extensive set of tools to transform population health activities ... and lifestyle data. higi collects and secures ...
(Date:3/24/2017)... , March 24, 2017 The Controller General ... Controller Mr. Abdulla Algeen have received the prestigious international IAIR ... Continue Reading ... ... picture) and Deputy Controller Abdulla Algeen (small picture on the right) have ...
Breaking Biology News(10 mins):